Print

2021/2022 Universal Influenza Immunization Program (UIIP)

The following provides information about the Ontario Ministry of Health (the ministry's) Universal Influenza Immunization Program (UIIP) for the 2021/2022 influenza season. The UIIP offers influenza vaccine free of charge each year to all individuals six months of age and older who live, work or go to school in Ontario.

Vaccination against influenza will be important this fall given the potential for the co-circulation of COVID-19. Preventing the flu will be important not only to protect individual health and the health of families and communities, but also to protect and mitigate impacts on our health care system. 

Contents

Immunization of High-Risk Groups

Per the National Advisory Committee on Immunization (NACI), individuals in the following four groups are particularly recommended to receive the influenza vaccine:

  1. Individuals at high risk of influenza-related complications or who are more likely to require hospitalization:
    • All pregnant women
    • People who are residents of nursing homes or other chronic care facilities
    • People ≥ 65 years of age
    • All children 6 months to 4 years of age
    • Indigenous peoples
    • Adults or children 6 months of age and over with chronic health conditions as follows:
      • Cardiac or pulmonary disorders
      • Diabetes mellitus or other metabolic disease
      • Cancer
      • Conditions or medication which compromise the immune system (due to underlying disease, therapy or both)
      • Renal disease
      • Anemia or hemoglobinopathy
      • Neurologic or neurodevelopment conditions
      • Morbid obesity (body mass index of ≥ 40)
      • Children and adolescents (6 months to 18 years) undergoing treatment with acetylsalicylic acid for long periods
  2. Individuals capable of transmitting influenza to those listed in #1 and/or to infants under 6 months of age:
    • Health care workers and other care providers in facilities and community settings
    • Household contacts (adults and children) of individuals at high risk of influenza related complications
    • Persons who provide care to children ≤ 4 years of age
    • Members of a household expecting a newborn during the influenza season
    • Those who provide services within a closed or relatively closed setting to persons at high risk (e.g., crew on a ship)
  3. People who provide essential community services
  4. Poultry industry workers

To reduce the risk of severe illness that could potentially arise from co-infection with COVID-19 and influenza, individuals who are at high risk of severe COVID-19 related illness or those capable of transmitting influenza to those at high risk of severe and critical illness related to COVID-19 are particularly recommended to receive the influenza vaccine this fall.

Influenza immunization should be prioritized as follows:

Month Populations
End of Sept to early-Oct
  • Hospitalized individuals and hospital staff
  • LTCH residents and staff
October
  • Individuals at high-risk for flu related complications or hospitalization
    (group 1) and health care providers
November
  • General population (including groups 2, 3 and 4)

UIIP Influenza Vaccine Products

The publicly funded influenza vaccines available for the 2021/2022 UIIP include:

Table 1. Publicly funded influenza vaccine available through the 2021/2022 UIIP for individuals 6 months of age and older
  Quadrivalent Inactivated Vaccine
UIIP Abbreviation QIV
NACI Abbreviation IIV4-SD     IIV4-cc
Vaccine product FluLaval Tetra Fluzone® Quadrivalent Afluria® Tetra Flucelvax® Quad
Manufacturer GSK Sanofi Pasteur Seqirus Seqirus

Age indication

≥6 months

≥6 months

≥5 years

≥2 years

Vaccine type

Egg-based

Egg-based

Egg-based

Cell culture-based1

Micrograms of hemagglutinin

15 µg

15 µg

15 µg

15 µg

Dosage 0.5 mL

0.5 mL

0.5 mL 0.5 mL
Format MDV

1. MDV
2. PFS

1. MDV
2. PFS
PFS
Route IM IM IM IM
Most common allergens2
  • Egg protein3
  • Thimerosal4
  • Egg protein3
  • Thimerosal4
  • Egg protein3
  • Neomycin
  • Polymyxin B
  • Thimerosal4
Does NOT contain egg protein
Post-puncture shelf life 28 days5 MDV: 28 days5
PFS: Not applicable
MDV: 28 days5
PFS: Not applicable
Not applicable
Product dimensions (cm) 2.7 x 2.7 x 6.9 MDV: 3 x 2.9 x 6.2
PFS: 10.4 x 9.9 x 3.8
MDV: 6.1x 6.0 x 3.1
PFS: 12.5 x 6.1 x 9.4
15.4 x 13.02 x 2.38
  1. ‘Cell culture-based’ refers to how the influenza vaccine is made. Flucelvax® Quad is a mammalian cell culture-based QIV. Both egg-based and cell culture-based QIVs provide protection against four strains of influenza and are available in the UIIP for 2021/2022. Any of the available products can be used in the age group for which they are indicated.
  2. Any component in a vaccine may be a potential allergen. This table identifies the most common allergens.
  3. The National Advisory Committee on Immunization (NACI) indicates that egg allergy is not a contraindication for influenza vaccination and that egg-allergic individuals may be vaccinated against influenza using the full dose of any age-appropriate product.
  4. Multi-dose vial presentation only
  5. Return vials with remaining doses to PHU or OGPMSS (for Toronto clients) as wastage.

Table 2. Publicly funded influenza vaccine available through the 2021/2022 UIIP for individuals 65 years of age and older

 

High-Dose Quadrivalent Inactivated Vaccine

Adjuvanted Trivalent Inactivated Vaccine

UIIP Abbreviation QIV-HD

TIV-adj

NACI Abbreviation IIV4-HD

IIV3-Adj

Vaccine product Fluzone® High-Dose Quadrivalent

Fluad®

Manufacturer Sanofi Pasteur

Seqirus

Age indication ≥65 years

≥65 years

Vaccine type Egg-based

Egg-based

Micrograms of hemagglutinin 60 µg

15 µg

Dosage 0.7 mL

0.5 mL

Adjuvant No

Yes

Format PFS

PFS

Route IM

IM

Most common allergens1
  • Egg protein2
  • Egg protein2
  • Kanamycin
  • Neomycin
Post-puncture shelf life Not applicable

Not applicable

Product dimensions (cm) 9.9 x 10.4 x 2.3

12.7 x 6.35 x 9.4

  1. Any component in a vaccine may be a potential allergen. This table identifies the most common allergens.
  2. The National Advisory Committee on Immunization (NACI) indicates that egg allergy is not a contraindication for influenza vaccination and that egg-allergic individuals may be vaccinated against influenza using the full dose of any age-appropriate product.

Important Notes:

UIIP Vaccines for Specific Age Groups: Product Availability

Age Group

QIV

QIV-HD

TIV-adj

FluLaval Tetra

Fluzone® Quadrivalent

Flucelvax® Quad

Afluria® Tetra

Fluzone®
High-Dose Quadrivalent

Fluad®

6 months to 1 year

 

 

 

 

2 to 4 years

 

 

 

5 to 64 years

 

 

≥ 65 years

Timing of Product Availability

Table 3: Annual UIIP Vaccine Supply Timeline
  Provincial Vaccine Supply
Mid to late-September The province begins receiving its initial supply of influenza vaccine doses in multiple shipments from manufacturers over several weeks. Initial supply is prioritized for hospitals and long-term care homes.
Early- to mid-October The province continues to receive shipments of influenza vaccine throughout October from the manufacturers for distribution to all providers.

As provincial stocks are replenished, deliveries continue with priority to retirement homes, congregate care settings and then primary care and pharmacies.
Mid to late-October Provincial influenza vaccine supply is replenished following initial distribution and additional shipments from vaccine manufacturers.

Deliveries and orders continue across the province and settings.
November onward Province orders additional doses as required from vaccine manufacturers.

Deliveries and orders continue across the province and settings.

Vaccine Wastage and Cold Chain Requirements

Program Specific Information

Additional Resources and Information

Questions

For More Information

Please e-mail uiip.moh@ontario.ca or call Service Ontario, INFOline at 1 877-844-1944